Bone Marrow Diseases
Also known as: Disorder, Syndrome, Diseases, Condition, Hyperplastic marrow
Methodology & AI Transparency ⓘ
Bone Marrow Diseases Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Bone marrow is the spongy tissue inside some of your bones, such as your hip and thigh bones.
- 2 Real-world patient consensus: Mapped to Cancer, Oncology & Supportive Care under ICD-10-CM D45 for Bone Marrow Diseases clinical workups.
- 3 Typical cash cost range: Clinicians assessing Bone Marrow Diseases focus on immune-checkpoint evasion [Bone Marrow Diseases D45] and targeted history.
- 4 Top reported side effects / signs: Longitudinal Bone Marrow Diseases monitoring tracks Complete Blood Count in Bone Marrow Diseases (D45: (ANC, Hemoglobin, Platelets)) toward Safe hematologic reserve (D45).
Ask our AI Specialists anything about Bone Marrow Diseases
What Is Bone Marrow Diseases?
Bone marrow is the spongy tissue inside some of your bones, such as your hip and thigh bones. It contains stem cells . The stem cells can develop into the red blood cells that carry oxygen through your body, the white blood cells that fight infections, and the platelets that help with blood clotting.
Pathophysiology, Underlying Causes & Clinical Presentation
In Bone Marrow Diseases (D45), physiological disruption stems from immune-checkpoint evasion [Bone Marrow Diseases D45], Cross-referenced with NIH MeSH (Bone Marrow Diseases), informing Cancer, Oncology & Supportive Care protocols that track Comprehensive Metabolic & in Bone Marrow Diseases (D45: Organ Function Panel) (Preserved renal/hepatic clearance (D45)).
Common Symptoms & Clinical Signs
- • In leukemia , a cancer of the blood, the bone marrow makes abnormal white blood cells
- • In aplastic anemia , the bone marrow doesn't make red blood cells
- • Presentation of Bone Marrow Diseases (D45): unintended weight loss [Bone Marrow Diseases D45]
- • Secondary Bone Marrow Diseases clinical sign: unexplained bleeding, chronic in Bone Marrow Diseases (D45: hoarseness/cough, or progressive)
Primary Federal Reference: NIH / National Library of Medicine MedlinePlus Entry ↗
Bone Marrow Diseases Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | D45 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Cancer, Oncology & Supportive Care | NIH MedlinePlus Health Topics |
| Diagnostic / Lab Marker: Complete Blood Count in Bone Marrow Diseases (D45: (ANC, Hemoglobin, Platelets)) | Safe hematologic reserve (D45) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Comprehensive Metabolic & in Bone Marrow Diseases (D45: Organ Function Panel) | Preserved renal/hepatic clearance (D45) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Pathology / Molecular in Bone Marrow Diseases (D45: Genomic Staging) | Guideline-concordant surveillance (D45) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Bone Marrow Diseases
Treatment selection for Bone Marrow Diseases depends on clinical severity, diagnostic lab results, and medical history. Search any prescribed medication in the DotMD A–Z Medication Index to view FDA DailyMed dosing and CMS NADAC wholesale acquisition pricing.
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Bone Marrow Diseases)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Testosterone supplementation and bone: What a 3,103-Participant Study Found TRT is able to inhibit bone resorption and increase bone mass, particularly at the lumbar spine level and when the duration is long enough to allow the anabolic effect of T and estrogens on bone metabolism to take place. Journal of endocrinological investigation • 2022-05-15 • Meta-Analysis | N = 3,103 | 99/100 | PMID 35041193 ↗ |
| New Insights on Different Anti-Hyperglycaemic Treatments on Bone Turnover Markers and Bone: What a 4,914-Participant Study Found High heterogeneity and diverse follow-up durations among studies were evident, which obscures the validity of the results. International journal of molecular sciences • 2024-07-22 • Meta-Analysis | N = 4,914 | 99/100 | PMID 39063229 ↗ |
| New Insights on Contrasting Bone Profiles in PCOS Are Related to: What a 1,822-Participant Study Found The findings of this study alert for a low bone mass, low bone formation, and increased bone resorption PCOS with a BMI <27 kg/m2. The Journal of clinical endocrinology and metabolism • 2024-09-16 • Meta-Analysis | N = 1,822 | 94/100 | PMID 38739756 ↗ |
| New Insights on Effect of Pelvic External Beam Radiation Therapy on Bone Mineral Density: A: What a 447-Participant Study Found We did not find sufficient evidence to suggest any detrimental effect of pelvic XRT on the treatment effect from denosumab on percent BMD change, with only an approximately 5% incidence of clinical fractures. International journal of radiation oncology, biology, physics • 2024-05-01 • Phase III Randomized Trial | N = 447 | 93/100 | PMID 37924987 ↗ |
| New Insights on Benefits and safety of Denosumab Biosimilar QL1206 Versus Denosumab in Patients: What a 357-Participant Study Found Denosumab biosimilar QL1206 had promising efficacy, tolerable safety, and how the body absorbs the medicine equivalent to denosumab and could benefit patients with bone metastases from solid tumors. BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy • 2023-03-15 • Phase III Randomized Trial | N = 357 | 93/100 | PMID 36802320 ↗ |
Bone Marrow Diseases Patient Community & “People Like Me” Threads
Filter Bone Marrow Diseases community threads and patient logs by age, biological sex, dosage, and treatment duration.